The Kaiser Permanente-backed company, developer of treatments for heart aneurysms, raised the maximum target for its initial public offering from the initial $100m.
US-based medical device manufacturer TriVascular Technologies has amended its initial public offering, for which it originally filed in early March, and now intends to raise up to $112.1m by issuing almost 7.48 million shares priced at up to $15.00 each, up from the $100m initially targeted.
Founded in 2007, TriVascular manufactures medical devices capable of the minimally invasive treatment of abdominal aortic aneurysms. It intends to use $3.5m of the proceeds to repay a promissory note to Boston Scientific Corporation,…
